Connect your AI

Ginkgo Bioworks DNA Gain (Loss) On Investments And Income (Loss) From Equity Method Investments

Other financials

Income statement

Revenue$19.5M-49.1%

Gross profit$16.4M-52.0%

Operating income-$71.4M+11.9%

Net income-$82.6M+9.2%

EPS (diluted)-$1.42+27.6%

Balance sheet

Cash & equivalents$188.7M-46.9%

Total debt$410.7M-5.5%

Total equity$443.2M-31.6%

Total assets$1.0B-20.1%

Cash flow

Operating cash flow-$46.7M+9.4%

CapEx$1.9M-74.6%

Free cash flow-$48.6M+17.8%

Valuation

Market cap$625.16M+24.6%

Enterprise value$847.19M+45.9%

P/S4.4×+2.2×

Profitability

Operating margin-210.7%+7.6pp

Net margin-215.4%+8.3pp

FCF margin-119%-21.2pp

Returns & leverage

Return on equity-55.8%-1.8pp

Debt / equity0.9×+0.3×

Current ratio5.2×+0.3×

Where this comes from

Reported directly by Ginkgo Bioworks in its filing.

Tagged under the XBRL concept dna:GainLossOnInvestmentsAndIncomeLossFromEquityMethodInvestments.

The official record: Ginkgo Bioworks’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Ginkgo Bioworks's gain (loss) on investments and income (loss) from equity method investments.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Ginkgo Bioworks's gain (loss) on investments and income (loss) from equity method investments?: Ginkgo Bioworks (DNA) reported gain (loss) on investments and income (loss) from equity method investments of -$1.21M in Q1 2026.
How has Ginkgo Bioworks's gain (loss) on investments and income (loss) from equity method investments changed year-over-year?: Ginkgo Bioworks's gain (loss) on investments and income (loss) from equity method investments increased by 67.1% year-over-year, from -$3.69M to -$1.21M.